Peroxisome proliferator-activated receptor-γ 34C>G polymorphism and colorectal cancer risk: A meta-analysis

AIM: To investigate the association between peroxisome proliferator-activated receptor-γ (PPAR-γ) gene polymorphism 34 C>G and colorectal cancer (CRC), a meta-analysis review was performed in this report. METHODS: A systematic literature search and selection of eligible relevant studies were carried out. Nine independent studies with a total number of 4533 cases and 6483 controls were included in the meta-analysis on the association between polymorphism 34 C>G and CRC. RESULTS: There was no evidence for the association between PPAR-γ 34 C>G and CRC if all of the subjects in the nine studies were included. However, CG + GG showed a marginally significant difference from CC (OR = 0.84, 95% CI: 0.69-1.01, P = 0.07) in random-effect model. Stratified meta-analysis indicated that PPAR-γ 34 C>G was associated with colon cancer (OR = 0.8, 95% CI: 0.65-0.99, P = 0.04) in random-effect model, and the G allele decreased colon cancer risk. No significant association was observed between PPAR-γ 34 C>G and rectal cancer. CONCLUSION: PPAR-γ 34 C>G is associated with colon cancer risk, but not associated with CRC and rectal cancer risk.

[1]  Y. Guan,et al.  Clinical value of F-FDG PET/CT in assessing suspicious relapse after rectal cancer resection. , 2009, World journal of gastrointestinal oncology.

[2]  M. Gazouli,et al.  Undefined familial colorectal cancer. , 2009, World journal of gastrointestinal oncology.

[3]  C. O'Morain,et al.  Concept of chemoprevention in colorectal cancer. , 2009, World journal of gastrointestinal oncology.

[4]  K. Friedrich,et al.  Perspectives of colorectal cancer screening in Germany 2009. , 2009, World journal of gastrointestinal endoscopy.

[5]  U. Vogel,et al.  Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. , 2007, Mutation research.

[6]  S. Ingles,et al.  Peroxisome proliferator-activated receptor (PPAR) gamma gene polymorphisms and colorectal cancer risk among Chinese in Singapore. , 2006, Carcinogenesis.

[7]  M. Gazouli,et al.  Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. , 2006, World journal of gastroenterology.

[8]  P. Peeters,et al.  Polymorphisms in the genes involved in the arachidonic acid‐pathway, fish consumption and the risk of colorectal cancer , 2006, International journal of cancer.

[9]  R. Sinha,et al.  Inflammation-Related Gene Polymorphisms and Colorectal Adenoma , 2006, Cancer Epidemiology Biomarkers & Prevention.

[10]  Seiichi Nakamura,et al.  Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator‐activated receptor‐gamma on colorectal cancer in an Indian population , 2005, Cancer science.

[11]  R. Wolff,et al.  Interactions of Peroxisome Proliferator–Activated Receptor γ and Diet in Etiology of Colorectal Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[12]  Philippe Vielh,et al.  Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators , 2004 .

[13]  R. Bostick,et al.  The PPARγ Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas , 2004 .

[14]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists , 2004 .

[15]  R. Broaddus,et al.  Arachidonic acid and colorectal carcinogenesis , 2003, Molecular and Cellular Biochemistry.

[16]  Stefano Landi,et al.  Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. , 2003, Cancer research.

[17]  H. Nakagama,et al.  Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. , 2003, Gastroenterology.

[18]  A. Terano,et al.  Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells , 2002, Gut.

[19]  W. Lau,et al.  Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. , 2002, Life sciences.

[20]  E. Van Cutsem,et al.  Molecular and genetic defects in colorectal tumorigenesis. , 2002, Best practice & research. Clinical gastroenterology.

[21]  C. Plass,et al.  Over-representation of PPARγ sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population , 2000, Journal of medical genetics.

[22]  R. Bostick,et al.  The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas. , 2005, Carcinogenesis.

[23]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. , 2004, The Lancet. Oncology.

[24]  Philippe Vielh,et al.  Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. , 2004, Cancer treatment reviews.

[25]  A. Terano,et al.  Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. , 2002, Gut.